Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Highlights on MRI of the fetal body.

Manganaro L, Antonelli A, Bernardo S, Capozza F, Petrillo R, Satta S, Vinci V, Saldari M, Maccioni F, Ballesio L, Catalano C.

Radiol Med. 2018 Apr;123(4):271-285. doi: 10.1007/s11547-017-0834-7. Epub 2017 Nov 21. Review.

PMID:
29164364
2.

Early and late onset complications of gynaecologic surgery: a multimodality imaging approach.

De Blasis I, Vinci V, Sergi ME, Capozza F, Saldari M, Moro F, Moruzzi MC, Testa AC, Manganaro L.

Facts Views Vis Obgyn. 2017 Mar;9(1):5-14. Review.

3.

Role of magnetic resonance imaging in the prenatal diagnosis of gastrointestinal fetal anomalies.

Manganaro L, Saldari M, Bernardo S, Vinci V, Aliberti C, Sollazzo P, Giancotti A, Capozza F, Porpora MG, Cozzi DA, Catalano C.

Radiol Med. 2015 Apr;120(4):393-403. doi: 10.1007/s11547-014-0464-2. Epub 2014 Oct 28.

PMID:
25348138
4.

Cav1 inhibits benign skin tumor development in a two-stage carcinogenesis model by suppressing epidermal proliferation.

Trimmer C, Sotgia F, Lisanti MP, Capozza F.

Am J Transl Res. 2013;5(1):80-91. Epub 2013 Jan 21.

5.

Adrenal lesions: spectrum of imaging findings with emphasis on multi-detector computed tomography and magnetic resonance imaging.

Guerrisi A, Marin D, Baski M, Guerrisi P, Capozza F, Catalano C.

J Clin Imaging Sci. 2013 Dec 31;3:61. doi: 10.4103/2156-7514.124088. eCollection 2013.

6.

Cav1 suppresses tumor growth and metastasis in a murine model of cutaneous SCC through modulation of MAPK/AP-1 activation.

Trimmer C, Bonuccelli G, Katiyar S, Sotgia F, Pestell RG, Lisanti MP, Capozza F.

Am J Pathol. 2013 Mar;182(3):992-1004. doi: 10.1016/j.ajpath.2012.11.008. Epub 2012 Dec 22.

7.

The milk protein α-casein functions as a tumor suppressor via activation of STAT1 signaling, effectively preventing breast cancer tumor growth and metastasis.

Bonuccelli G, Castello-Cros R, Capozza F, Martinez-Outschoorn UE, Lin Z, Tsirigos A, Xuanmao J, Whitaker-Menezes D, Howell A, Lisanti MP, Sotgia F.

Cell Cycle. 2012 Nov 1;11(21):3972-82. doi: 10.4161/cc.22227. Epub 2012 Oct 9.

8.

Genetic ablation of Cav1 differentially affects melanoma tumor growth and metastasis in mice: role of Cav1 in Shh heterotypic signaling and transendothelial migration.

Capozza F, Trimmer C, Castello-Cros R, Katiyar S, Whitaker-Menezes D, Follenzi A, Crosariol M, Llaverias G, Sotgia F, Pestell RG, Lisanti MP.

Cancer Res. 2012 May 1;72(9):2262-74. doi: 10.1158/0008-5472.CAN-11-2593. Epub 2012 Mar 6.

9.

Matrix remodeling stimulates stromal autophagy, "fueling" cancer cell mitochondrial metabolism and metastasis.

Castello-Cros R, Bonuccelli G, Molchansky A, Capozza F, Witkiewicz AK, Birbe RC, Howell A, Pestell RG, Whitaker-Menezes D, Sotgia F, Lisanti MP.

Cell Cycle. 2011 Jun 15;10(12):2021-34. Epub 2011 Jun 15.

10.

Role of cholesterol in the development and progression of breast cancer.

Llaverias G, Danilo C, Mercier I, Daumer K, Capozza F, Williams TM, Sotgia F, Lisanti MP, Frank PG.

Am J Pathol. 2011 Jan;178(1):402-12. doi: 10.1016/j.ajpath.2010.11.005. Epub 2010 Dec 23.

11.

Caveolin-1 and mitochondrial SOD2 (MnSOD) function as tumor suppressors in the stromal microenvironment: a new genetically tractable model for human cancer associated fibroblasts.

Trimmer C, Sotgia F, Whitaker-Menezes D, Balliet RM, Eaton G, Martinez-Outschoorn UE, Pavlides S, Howell A, Iozzo RV, Pestell RG, Scherer PE, Capozza F, Lisanti MP.

Cancer Biol Ther. 2011 Feb 15;11(4):383-94. Epub 2011 Feb 15.

12.

Autophagy in cancer associated fibroblasts promotes tumor cell survival: Role of hypoxia, HIF1 induction and NFκB activation in the tumor stromal microenvironment.

Martinez-Outschoorn UE, Trimmer C, Lin Z, Whitaker-Menezes D, Chiavarina B, Zhou J, Wang C, Pavlides S, Martinez-Cantarin MP, Capozza F, Witkiewicz AK, Flomenberg N, Howell A, Pestell RG, Caro J, Lisanti MP, Sotgia F.

Cell Cycle. 2010 Sep 1;9(17):3515-33. Epub 2010 Sep 9.

13.

CAV1 inhibits metastatic potential in melanomas through suppression of the integrin/Src/FAK signaling pathway.

Trimmer C, Whitaker-Menezes D, Bonuccelli G, Milliman JN, Daumer KM, Aplin AE, Pestell RG, Sotgia F, Lisanti MP, Capozza F.

Cancer Res. 2010 Oct 1;70(19):7489-99. doi: 10.1158/0008-5472.CAN-10-0900. Epub 2010 Aug 13.

14.

The reverse Warburg effect: glycolysis inhibitors prevent the tumor promoting effects of caveolin-1 deficient cancer associated fibroblasts.

Bonuccelli G, Whitaker-Menezes D, Castello-Cros R, Pavlides S, Pestell RG, Fatatis A, Witkiewicz AK, Vander Heiden MG, Migneco G, Chiavarina B, Frank PG, Capozza F, Flomenberg N, Martinez-Outschoorn UE, Sotgia F, Lisanti MP.

Cell Cycle. 2010 May 15;9(10):1960-71. Epub 2010 May 15.

PMID:
20495363
15.

Caveolin-1 (P132L), a common breast cancer mutation, confers mammary cell invasiveness and defines a novel stem cell/metastasis-associated gene signature.

Bonuccelli G, Casimiro MC, Sotgia F, Wang C, Liu M, Katiyar S, Zhou J, Dew E, Capozza F, Daumer KM, Minetti C, Milliman JN, Alpy F, Rio MC, Tomasetto C, Mercier I, Flomenberg N, Frank PG, Pestell RG, Lisanti MP.

Am J Pathol. 2009 May;174(5):1650-62. doi: 10.2353/ajpath.2009.080648.

16.

Loss of caveolin-3 induces a lactogenic microenvironment that is protective against mammary tumor formation.

Sotgia F, Casimiro MC, Bonuccelli G, Liu M, Whitaker-Menezes D, Er O, Daumer KM, Mercier I, Witkiewicz AK, Minetti C, Capozza F, Gormley M, Quong AA, Rui H, Frank PG, Milliman JN, Knudsen ES, Zhou J, Wang C, Pestell RG, Lisanti MP.

Am J Pathol. 2009 Feb;174(2):613-29. doi: 10.2353/ajpath.2009.080653.

17.

Regulation of insulin receptor substrate-1 expression levels by caveolin-1.

Chen J, Capozza F, Wu A, Deangelis T, Sun H, Lisanti M, Baserga R.

J Cell Physiol. 2008 Oct;217(1):281-9. doi: 10.1002/jcp.21498.

PMID:
18506777
18.

Altered emotionality, spatial memory and cholinergic function in caveolin-1 knock-out mice.

Gioiosa L, Raggi C, Ricceri L, Jasmin JF, Frank PG, Capozza F, Lisanti MP, Alleva E, Sargiacomo M, Laviola G.

Behav Brain Res. 2008 Apr 9;188(2):255-62. Epub 2007 Nov 12.

PMID:
18083242
19.

Caveolin-1 is required for the upregulation of fatty acid synthase (FASN), a tumor promoter, during prostate cancer progression.

Di Vizio D, Sotgia F, Williams TM, Hassan GS, Capozza F, Frank PG, Pestell RG, Loda M, Freeman MR, Lisanti MP.

Cancer Biol Ther. 2007 Aug;6(8):1263-8. Epub 2007 May 17.

PMID:
17786030
20.

Localized treatment with a novel FDA-approved proteasome inhibitor blocks the degradation of dystrophin and dystrophin-associated proteins in mdx mice.

Bonuccelli G, Sotgia F, Capozza F, Gazzerro E, Minetti C, Lisanti MP.

Cell Cycle. 2007 May 15;6(10):1242-8. Epub 2007 May 27.

PMID:
17495527
21.

Caveolin-1(-/-)- and caveolin-2(-/-)-deficient mice both display numerous skeletal muscle abnormalities, with tubular aggregate formation.

Schubert W, Sotgia F, Cohen AW, Capozza F, Bonuccelli G, Bruno C, Minetti C, Bonilla E, Dimauro S, Lisanti MP.

Am J Pathol. 2007 Jan;170(1):316-33.

22.

Stromal and epithelial caveolin-1 both confer a protective effect against mammary hyperplasia and tumorigenesis: Caveolin-1 antagonizes cyclin D1 function in mammary epithelial cells.

Williams TM, Sotgia F, Lee H, Hassan G, Di Vizio D, Bonuccelli G, Capozza F, Mercier I, Rui H, Pestell RG, Lisanti MP.

Am J Pathol. 2006 Nov;169(5):1784-801.

23.

Caveolin-3 knockout mice show increased adiposity and whole body insulin resistance, with ligand-induced insulin receptor instability in skeletal muscle.

Capozza F, Combs TP, Cohen AW, Cho YR, Park SY, Schubert W, Williams TM, Brasaemle DL, Jelicks LA, Scherer PE, Kim JK, Lisanti MP.

Am J Physiol Cell Physiol. 2005 Jun;288(6):C1317-31. Epub 2005 Feb 2.

24.

Muscle-specific interaction of caveolin isoforms: differential complex formation between caveolins in fibroblastic vs. muscle cells.

Capozza F, Cohen AW, Cheung MW, Sotgia F, Schubert W, Battista M, Lee H, Frank PG, Lisanti MP.

Am J Physiol Cell Physiol. 2005 Mar;288(3):C677-91. Epub 2004 Nov 17.

25.

Tyrosine phosphorylation of caveolin-2 at residue 27: differences in the spatial and temporal behavior of phospho-Cav-2 (pY19 and pY27).

Wang XB, Lee H, Capozza F, Marmon S, Sotgia F, Brooks JW, Campos-Gonzalez R, Lisanti MP.

Biochemistry. 2004 Nov 2;43(43):13694-706.

PMID:
15504032
26.
27.

Phenotypic behavior of caveolin-3 R26Q, a mutant associated with hyperCKemia, distal myopathy, and rippling muscle disease.

Sotgia F, Woodman SE, Bonuccelli G, Capozza F, Minetti C, Scherer PE, Lisanti MP.

Am J Physiol Cell Physiol. 2003 Nov;285(5):C1150-60. Epub 2003 Jul 2.

28.

Absence of caveolin-1 sensitizes mouse skin to carcinogen-induced epidermal hyperplasia and tumor formation.

Capozza F, Williams TM, Schubert W, McClain S, Bouzahzah B, Sotgia F, Lisanti MP.

Am J Pathol. 2003 Jun;162(6):2029-39.

29.

Intracellular retention of glycosylphosphatidyl inositol-linked proteins in caveolin-deficient cells.

Sotgia F, Razani B, Bonuccelli G, Schubert W, Battista M, Lee H, Capozza F, Schubert AL, Minetti C, Buckley JT, Lisanti MP.

Mol Cell Biol. 2002 Jun;22(11):3905-26.

30.

Caveolin-1 expression negatively regulates cell cycle progression by inducing G(0)/G(1) arrest via a p53/p21(WAF1/Cip1)-dependent mechanism.

Galbiati F, Volonté D, Liu J, Capozza F, Frank PG, Zhu L, Pestell RG, Lisanti MP.

Mol Biol Cell. 2001 Aug;12(8):2229-44.

31.
32.

[Long term central venous catheterization revisited].

Palermo S, Campolucci A, Capozza F, Cammardella MP, Balestrero A, Ferrando F, Basta P, Launo C.

Minerva Anestesiol. 1995 Nov;61(11):451-6. Italian.

PMID:
8677035
33.

Persistence of antibodies to rotavirus in human milk.

Cukor G, Blacklow NR, Capozza FE, Panjvani ZF, Bednarek F.

J Clin Microbiol. 1979 Jan;9(1):93-6.

34.

Secretory IgA antibody to rotavirus in human milk 6--9 months postpartum.

Cukor G, Blacklow N, Capozza F, Panjvani Z, Bednarek F.

Lancet. 1978 Sep 16;2(8090):631-2. No abstract available.

PMID:
80554
35.

Supplemental Content

Loading ...
Support Center